Prediction of herb-drug metabolic interactions: A simulation study

Phytotherapy Research

Volumn 19, Issue 6, 2005, Pages 464-471

  Zhou, Shufeng ^a   Huang, Min ^b   Xu, Anlong ^b   Yang, Hongyuan ^c   Duan, Wei ^c   Paxton, James W ^d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SUN YAT SEN UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cytochrome P450; Drug interactions; Herb; Metabolic inhibition

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CARBAMAZEPINE; CHLORPROPAMIDE; CYCLOSPORIN; DIGOXIN; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; KAVA EXTRACT; LOPERAMIDE; NEFAZODONE; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENPROCOUMON; PHENYTOIN; PIPERINE; PROPRANOLOL; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIMVASTATIN; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TRAZODONE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; BREAKTHROUGH BLEEDING; COMA; CONSCIOUSNESS DISORDER; DELIRIUM; DRUG CLEARANCE; DRUG METABOLISM; HERB DRUG INTERACTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; ORAL DRUG ADMINISTRATION; SEROTONIN SYNDROME; SIMULATION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; HERB-DRUG INTERACTIONS; HUMANS; INJECTIONS, INTRAVENOUS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; PREDICTIVE VALUE OF TESTS;

ANIMALIA;

EID: 25144524302     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1559     Document Type: Article

References (52)

1. Allen SW, Mueller L, Williams SN, et al. 2001. The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human CYP1A1 expression. Drug Metab Dispos 29: 1074-1079.
2. Almeida JC, Grimsley EW. 1996. Coma from the health food store: Interaction between Kava and Alprazolam. Ann Int Med 125: 940-941.
3. Bano G, Amla V, Raina RK, et al. 1987. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 53: 568-569.
4. Bano G, Raina RK, Zutshi U, et al. 1991. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 41: 615-617.
5. Bergonzi MC, Bilia AR, Gallori S, et al. 2001. Variability in the content of the constituents of Hypericum perforatum L. and some commercial extracts. Drug Develop Industr Pharm 27: 491-497.
6. Biffignandi PM, Bilia AR. 2000. The growing knowledge of St. John's wort (Hypericum perforatum L) drug interactions and their clinical significance. Curr Ther Res 61: 389-394.
7. Breidenbach T, Kliem V, Burg M, et al. 2000. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation 69: 2229-2230.
8. Burchell B, Brierley CH, Monaghan G, Clarke DJ. 1998. The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 42: 335-338.
9. Burstein AH, Horton RL, Dunn T, et al. 2000. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 68: 605-612.
10. Chi JD, Franklin M. 1999. Determination of hypericin in plasma by high-performance liquid chromatography. J Chromatogy (B) 724: 195-198.
11. de Maat MM, Hoetelmans RM, Math t RA, et al. 2001. Drug interaction between St John's wort and nevirapine. AIDS 15: 420-421.
12. Dresser GK, Spence JD, Bailey DG. 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38: 41-57.
13. Durr D, Stieger B, Kullak-Ublick GA, et al. 2000. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68: 598-604.
14. Ekins S, Erickson JA. 2002. A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 30: 96-99.
15. Ekins S, Schuetz E. 2002. The PXR crystal structure: the end of the beginning. Trends Pharmacol Sci 23: 49-50.
16. Elvin-Lewis M. 2001. Should we be concerned about herbal remedies. J Ethnopharmacol 75: 141-164.
17. Fox E, Murphy RF, McCully CL, Adamson PC. 2001. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 47: 41-44.
18. Galluzzi S, Zanetti O, Binetti G, et al. 2000. Coma in a patient with Alzheimer's disease taking low dose trazodone and Ginkgo biloba. J Neurol Neurosurg Psychiatr 68: 679-680.
19. Goodwin B, Moore LB, Stoltz CM, et al. 2001. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60: 427-431.
20. Heck AM, DeWitt BA, Lukes AL. 2000. Potential interactions between alternative therapies and warfarin. Am J Health-System Pharm 57: 1221-1227.
21. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469-1479.
22. Ingram KD, Dragosavac GB, Benner KG, Flora KD. 2000. Risks of drug interactions with St John's Wort. Am J Gastroenterol 95: 3323-3324.
23. Ito K, Iwatsubo T, Kanamitsu S, et al. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50: 387-411.
24. Izzo AA, Capasso R, Pinto L, et al. 2001. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 132: 1411-1416.
25. Izzo AA, Ernst E. 2001. Interactions between herbal medicines and prescribed drugs - A systematic review. Drugs 61: 2163-2175.
26. Johne A, Brockmoller J, Bauer S, et al. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338-345.
27. Johne A, Schmider J, Brockmoller J, et al. 2002. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's Wort (Hypericum perforatum). J Clin Psychopharmacol 22: 46-54.
28. Kroemer HK, Klotz U. 1992. Glucuronidation of drugs: a reevaluation of the pharmacological significance of the conjugates and modulation factors. Clin Pharmacokinet 23: 292-310.
29. Lin JH. 1998. Application and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202-1212.
30. Masimirembwa CM, Thompson R, Andersson TB. 2001. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Combinatorial Chem High Throughput Screening 4: 245-263.
31. Maurer A, Johne A, Bauer S. 1999. Interaction of St. John's wort extract with phenprocoumon. Eur J Clin Pharmacol 55: 22.
32. Meech R, Mackenzie PI. 1997. Structure and function of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol 24: 907-915.
33. Moore LB, Goodwin B, Jones SA, et al. 2000. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500-7502.
34. Moschella C, Jaber BL. 2001. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am J Kidney Dis 38: 1105-1107.
35. Nebel A, Schneider BJ, Baker RK, Kroll DJ. 1999. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 33: 502.
36. Obach RS. 2000a. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294: 88-95.
37. Obach RS. 2000b. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 28: 1069-1076.
38. Owen A, Pirmohamed M, Tettey JN, et al. 2001. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 51: 345-349.
39. Pelkonen O, Myllynen P, Taavitsainen P, et al. 2001. Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31: 321-343.
40. Piscitelli SC, Burstein AH, Chain D, et al. 2000. Indinavir concentrations and St John's wort. Lancet 355: 547-548.
41. Piscitelli SC, Burstein AH, Welden N, et al. 2001. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34: 234-238.
42. Rendic S, Di Carlo FJ. 1997. Human cytochrome P450 enzyme: A status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab Rev 29: 413-580.
43. Staffeldt B, Kerb R, Brockmoller J, et al. 1993. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract Li 160 in healthy volunteers. Nervenheilkunde 12: 331-338.
44. Sugimoto K, Ohmori M, Tsuruoka S, et al. 2001. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518-524.
45. Tateishi T, Asoh M, Nakura H, et al. 1999. Carbamazepine induces multiple cytochrome P450 subfamilies in rats. Chem-Biol Interact 117: 257-268.
46. Teyssier C, Guenot L, Suschetet M, Siess MH. 1999. Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab Dispos 27: 835-841.
47. Tolonen A, Uusitalo J, Hohtola A, Jalonen J. 2002. Determination of naphthodianthrones and phloroglucinols from Hypericum perforatum extracts by liquid chromatography/tandem mass spectrometry. Rapid Communicat Mass Spectrometr 16: 396-402.
48. Tucker GT. 1992. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30: 550-553.
49. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease, Ann Rev Pharmacol Toxicol 40: 581-616.
50. von Moltke LL, Greenblatt DJ, Schmider J, et al. 1998. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55: 113-122.
51. Wentworth JM, Agostini M, Love J, et al. 2000. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 166: R11-16.
52. Yue QY, Bergquist C, Gerden B. 2000. Safety of St John's wort (Hypericum perforatum). Lancet 355: 548-549.